DISCOVER INDIA

The Emerging Hub for Generics Market

India’s generics market size was valued at $24.53 bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 6.97% from 2022 to 2028 and will reach $36.41 bn in 2028.

Generics 02

In the Indian generic drugs market, the top three therapeutic segments are Small molecule generics, accounting for 70.01% of the market, Hormones, accounting for 8.03%, and Anti-diabetics, accounting for 9.08%.

In the Indian generics market, the top distribution channels are hospital pharmacies, accounting for 35% of the market, retail pharmacies account for 25%, and Online pharmacies for 10%.

Key Growth Drivers Fuelling Market ā€‹

India, home to the world’s second-largest diabetic population and over 300 million people affected by hypertension, anticipates a 25% increase in cancer incidence by 2030. This drives the demand for long-term generic drug treatments.

The Indian healthcare system is facing several challenges, including rising costs and a shortage of doctors and hospitals. This has led to an increasing demand for affordable healthcare options, such as generic drugs.Ā 

The Indian government’s investment of over $1 billion in the past five years, along with financial assistance and tax incentives, is making generic drugs more affordable and accessible.

Indian pharmaceutical companies are poised to invest over $10 billion in R&D over the next five years to develop innovative generic drugs, enhancing their quality and efficacy, as reported by the Indian Pharmaceutical Alliance.

NAVIGATING THE REGULATORY LANDSCAPE

Step-by-Step Registration Process

Obtain an Authorized Representative

A foreign manufacturer must first obtain an authorized representative in India. The authorized representative will be responsible for registering the drugs and ensuring that they comply with Indian regulations.

Classify the Drug

The first step in the registration process is to classify the drug. The drug will be classified as either a Schedule X drug, a Schedule Y drug, or a Schedule Z drug. The classification of the drug will determine the level of regulatory scrutiny that it will be subject to.

Submit an Application

The foreign manufacturer must then submit an application to the Central Drugs Standard Control Organization (CDSCO) for registration of the drug. The application must include a variety of information, such as the name of the drug, the composition of the drug, the manufacturing process, and the clinical data for the drug.

Conduct Clinical Trials

If the drug is a new drug, the foreign manufacturer will need to conduct clinical trials in India to demonstrate the safety and efficacy of the drug. The clinical trials must be conducted in accordance with the guidelines of the CDSCO.

Obtain Approval

Once the application has been reviewed and approved by the CDSCO, the drug will be granted registration. The registration will be valid for five years and can be renewed.

Marketing in India

Once the process is completed the products can successfully market and sell in India. The IAR must ensure compliance with reporting changes, adverse events, recalls, to the CDSCO, if any.

Our Services

Empowering your Success in the Indian Market ā€‹

Taevas is at the forefront of this expansion, supporting businesses as they navigate and conquer new markets. Our comprehensive range of services for the life sciences include

Market access solutions
Embarking on Success with Taevas

Embarking on Success with Taevas

Taevas stands ready to serve as your custom-fit partner in India, catering to your unique business requirements.

As Your Market Entry Partner
  • As your Indian Authorized Representative (IAR), we ensure your regulatory compliance
  • We identify potential distributors for your products and facilitate initial connections
  • You will lead the further development of these distributor relationships
As Your Commercial Partner
  • Along with being your IAR, we also act as your centralized distributor in India
  • We identify and appoint local distributors in different regions of India, creating a wide and efficient distribution network
  • You can focus on your core business, while we handle the complexities of distribution
As Your Operational Partner
  • Along with being your IAR, we also initiate the building of your local presence in India
  • We put together a dedicated team who takes charge of sales partnerships and manages the nuances of business operations
  • We ā€˜Buildā€™ the infrastructure and set up processes; we ā€˜Operateā€™ the business, and when you feel ready, we ā€˜Transferā€™ the control to you